P1NP

Biomarker2 papers1 finding

Human trial1
Humans1

Interventions

1

Romosozumab

downin humans1

1 study

Romosozumab decreases P1NP in humans (median -16.4% vs. -19.6%).
Humansosteoporosissubcutaneous210 mg monthly12 months
Equivalent Twelve-Month Bone Mineral Density Response to Romosozumab in Patients Aged ≥ 85 Years and < 85 Years: A Multi-center Real-World Cohort Study (n = 417) from Northern Japan · Calcified tissue international · 25 Sep 2026

Romosozumab →

Latest

2

Journal of Clinical DensitometryHuman trial30 Sep

Combined baseline P1NP and TRAcP5b classification predicts differential bone mineral density response to romosozumab: A retrospective cohort study of 287 postmenopausal women

Calcified Tissue InternationalHumans26 Sep

Equivalent Twelve-Month Bone Mineral Density Response to Romosozumab in Patients Aged ≥ 85 Years and < 85 Years: A Multi-center Real-World Cohort Study (n = 417) from Northern Japan